Personalized Cognitive Therapy via Endophenotype Biomarker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cognitive decline and dementia, such as Alzheimer's disease, are ineffective due to a one-size-fits-all approach and lack of strategies for prevention, with inflammation being a common underlying factor across various diseases.
Innovation Solution
The method involves identifying specific endophenotypes, such as pro-inflammatory and metabolic endophenotypes, through biomarker analysis in blood or serum samples, and administering targeted therapies like NSAIDs or PPAR-γ agonists based on these profiles to improve cognition or prevent decline.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a one-size-fits-all approach is used for treating cognitive decline, then treatment simplicity is maintained, but treatment effectiveness deteriorates
Solution Approach 1:
The patent segments patients into distinct endophenotypic subgroups (e.g., proinflammatory, metabolic, neurotrophic) based on biomarker profiles. This segmentation allows for tailored treatment approaches for each subgroup rather than a uniform treatment strategy, thereby improving treatment effectiveness while managing complexity through systematic classification.
Solution Approach 2:
The patent applies local quality by matching specific treatments to specific patient subgroups based on their biomarker profiles. Each endophenotypic subgroup receives a customized treatment regimen (e.g., anti-inflammatory drugs for proinflammatory subgroups, PPAR-gamma agonists for metabolic subgroups), ensuring that the treatment quality is optimized for each patient's specific biological characteristics.
2Measurement precision
If biomarker analysis is performed to identify endophenotypes, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The diagnostic process is segmented into distinct steps: sample collection, biomarker measurement, endophenotype classification, and treatment recommendation. This segmentation makes the complex diagnostic process more manageable and systematic, allowing for high measurement precision through focused assessment of specific biomarker panels for each endophenotype.
Solution Approach 2:
The patent employs a universal biomarker panel that can identify multiple endophenotypic subgroups simultaneously. The same set of biomarkers (e.g., inflammatory markers, metabolic markers, neurotrophic factors) serves multiple diagnostic purposes by distinguishing between different patient subgroups, thereby improving diagnostic precision without proportionally increasing diagnostic complexity.
3Reliability
If personalized treatment based on endophenotypes is implemented, then cognitive outcome improvement is enhanced, but treatment cost increases
Solution Approach 1:
The patent implements partial action by measuring a selective panel of biomarkers relevant to each endophenotype rather than comprehensive profiling. For example, only proinflammatory markers are measured for proinflammatory endophenotypes, and only metabolic markers for metabolic endophenotypes. This partial measurement approach reduces diagnostic and treatment costs while maintaining the precision needed for cognitive outcome improvement.
Data Source
AI summary
The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-7 agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-7 agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-7 agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.